COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
COM902是一种靶向TIGIT的新型治疗性抗体,与PVRIG或PD-1通路阻断剂联合使用可增强抗肿瘤T细胞功能。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-021-02921-8
Hansen, Kyle; Kumar, Sandeep; Logronio, Kathryn; Whelan, Sarah; Qurashi, Samir; Cheng, Hsin-Yuan; Drake, Andrew; Tang, Margaret; Wall, Patrick; Bernados, David; Leung, Ling; Ophir, Eran; Alteber, Zoya; Cojocaru, Gady; Galperin, Moran; Frenkel, Masha; White, Mark; Hunter, John; Liang, Spencer C; Kotturi, Maya F
细胞生物学
肿瘤
T细胞
TIGIT
免疫/内分泌
肿瘤免疫
PVR
信号转导
T细胞
PD-1